These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28674847)

  • 1. A new integrated dual time-point amyloid PET/MRI data analysis method.
    Cecchin D; Barthel H; Poggiali D; Cagnin A; Tiepolt S; Zucchetta P; Turco P; Gallo P; Frigo AC; Sabri O; Bui F
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2060-2072. PubMed ID: 28674847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
    Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET - Application to amyloid imaging with AV45-PET.
    Gonzalez-Escamilla G; Lange C; Teipel S; Buchert R; Grothe MJ;
    Neuroimage; 2017 Feb; 147():669-677. PubMed ID: 28039094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of early-phase [
    Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
    Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification.
    Alongi P; Sardina DS; Coppola R; Scalisi S; Puglisi V; Arnone A; Raimondo GD; Munerati E; Alaimo V; Midiri F; Russo G; Stefano A; Giugno R; Piccoli T; Midiri M; Grimaldi LME
    J Neuroimaging; 2019 May; 29(3):383-393. PubMed ID: 30714241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
    Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
    Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI.
    Akamatsu G; Ikari Y; Ohnishi A; Nishida H; Aita K; Sasaki M; Yamamoto Y; Sasaki M; Senda M
    Phys Med Biol; 2016 Aug; 61(15):5768-80. PubMed ID: 27405579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification.
    Presotto L; Iaccarino L; Sala A; Vanoli EG; Muscio C; Nigri A; Bruzzone MG; Tagliavini F; Gianolli L; Perani D; Bettinardi V
    Neuroimage Clin; 2018; 20():153-160. PubMed ID: 30094164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-Low-Dose
    Chen KT; Gong E; de Carvalho Macruz FB; Xu J; Boumis A; Khalighi M; Poston KL; Sha SJ; Greicius MD; Mormino E; Pauly JM; Srinivas S; Zaharchuk G
    Radiology; 2019 Mar; 290(3):649-656. PubMed ID: 30526350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
    Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
    J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks.
    Kang SK; Kim D; Shin SA; Kim YK; Choi H; Lee JS
    J Nucl Med; 2023 Apr; 64(4):659-666. PubMed ID: 36328490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of amyloid PET/CT with
    Ferrari C; Caputo P; Pisani AR; Nappi AG; Branca A; Lavelli V; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():142-152. PubMed ID: 31802055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Noninvasive Tracer Kinetic Analysis of
    Bullich S; Barthel H; Koglin N; Becker GA; De Santi S; Jovalekic A; Stephens AW; Sabri O
    J Nucl Med; 2018 Jul; 59(7):1104-1110. PubMed ID: 29175981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.
    Brendel M; Högenauer M; Delker A; Sauerbeck J; Bartenstein P; Seibyl J; Rominger A;
    Neuroimage; 2015 Mar; 108():450-9. PubMed ID: 25482269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes.
    Kim JP; Kim J; Kim Y; Moon SH; Park YH; Yoo S; Jang H; Kim HJ; Na DL; Seo SW; Seong JK
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1971-1983. PubMed ID: 31884562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.